Literature DB >> 29394506

When less is more (brain)-comment on "Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage".

Patrick D Lyden1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29394506      PMCID： PMC5867256          DOI： 10.1002/ana.25163

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  20 in total

Review 1.  Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.

Authors:  Sarkis Morales-Vidal; Michael J Schneck; Murray Flaster; José Biller
Journal:  Expert Rev Neurother       Date:  2012-02       Impact factor: 4.618

Review 2.  Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents.

Authors:  Thorsten Steiner; Jeffrey I Weitz; Roland Veltkamp
Journal:  Stroke       Date:  2017-04-11       Impact factor: 7.914

3.  Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).

Authors:  Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta
Journal:  Stroke       Date:  2017-05-15       Impact factor: 7.914

4.  Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.

Authors:  Melanie Dittmeier; Peter Kraft; Michael K Schuhmann; Felix Fluri; Christoph Kleinschnitz
Journal:  Thromb Haemost       Date:  2015-10-22       Impact factor: 5.249

5.  An ethical hierarchy for decision making during medical emergencies.

Authors:  Patrick D Lyden; Brett C Meyer; Thomas M Hemmen; Karen S Rapp
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 6.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

7.  Time is brain--quantified.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

8.  Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.

Authors:  J R Marler; B C Tilley; M Lu; T G Brott; P C Lyden; J C Grotta; J P Broderick; S R Levine; M P Frankel; S H Horowitz; E C Haley; C A Lewandowski; T P Kwiatkowski
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

9.  Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage.

Authors:  David J Seiffge; Georg Kägi; Patrik Michel; Urs Fischer; Yannick Béjot; Susanne Wegener; Marialuisa Zedde; Guillaume Turc; Charlotte Cordonnier; Peter S Sandor; Gilles Rodier; Andrea Zini; Manuel Cappellari; Sabine Schädelin; Alexandros A Polymeris; David Werring; Sebastian Thilemann; Ilaria Maestrini; Eivind Berge; Christopher Traenka; Jochen Vehoff; Gian Marco De Marchis; Monika Kapauer; Nils Peters; Gaia Sirimarco; Leo H Bonati; Marcel Arnold; Philippe A Lyrer; Emmanuel De Maistre; Andreas Luft; Dimtrios A Tsakiris; Stefan T Engelter
Journal:  Ann Neurol       Date:  2018-03-03       Impact factor: 10.422

10.  Thrombolysis in stroke despite contraindications or warnings?

Authors:  Benedikt Frank; James C Grotta; Andrei V Alexandrov; Erich Bluhmki; Patrick Lyden; Atte Meretoja; Nishant K Mishra; Ashfaq Shuaib; Nils G Wahlgren; Christian Weimar; Kennedy R Lees
Journal:  Stroke       Date:  2013-02-06       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.